Misonix has entered into a new five-year exclusive US distribution agreement with Anika Therapeutics Inc’s wholly owned subsidiary Anika Therapeutics Srl to sell and distribute Anika's Hyalomatrix product, a skin substitute based on hyaluronic acid technology.
Hyalomatrix is indicated for treatment of a wide range of acute and chronic wounds and will be a companion product for Misonix’s SonicOne Ultrasonic Wound Cleansing and Debridement System.
Anika will manufacture and supply finished product to Misonix, while Misonix will be responsible for all aspects of commercialization in the US.
The SonicOne is an ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures.
Misonix president and CEO Michael McManus said Anika’s Hyalomatrix skin substitute will hold an important position in their treatment protocol for advanced wound management and is synergistic to their own SonicOne product line.
"The addition of Hyalomatrix is consistent with our plan to leverage the value of our existing distribution organization by adding more high value products to our sales pipeline," McManus said.